TEVA Earnings & Financial Statements
Teva Pharmaceutical Industries Limited
$39.13
-$0.53(-1.34%)
63
Overall
75
Value
66
Tech
50
Quality
Market Cap
$46.22B
Volume
5.72M
52W Range
$18.83 - $40.79
Target Price
$43.18
TEVA earnings and financial statements: Teva Pharmaceutical Industries Limited's income statement, balance sheet and cash flow statement, annual and quarterly.
TEVA Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $17.26B | $16.54B | $15.85B | $14.93B | $15.88B |
| Cost of revenue | $8.32B | $8.48B | $8.20B | $7.95B | $8.28B |
| Operating income | $2.16B | -$303.00M | $433.00M | -$2.20B | $1.72B |
| EBITDA | $2.24B | -$224.00M | $531.00M | -$2.21B | $2.88B |
| Net income | $1.41B | -$1.64B | -$559.00M | -$2.45B | $417.00M |
| EPS (diluted) | - | $-1.45 | $-0.50 | $-2.12 | $0.38 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $40.75B | $39.33B | $43.48B | $44.01B | $47.67B |
| Total liabilities | $32.83B | $33.61B | $35.35B | $35.41B | $36.42B |
| Shareholders’ equity | $7.91B | $5.37B | $7.51B | $7.80B | $10.28B |
| Cash and equivalents | $3.56B | $3.30B | $3.23B | $2.80B | $2.17B |
| Long-term debt | $15.27B | $16.30B | $18.48B | $19.45B | $22.03B |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | $1.65B | $1.25B | $1.37B | $1.59B | $798.00M |
| Capital expenditure | -$501.00M | -$498.00M | -$526.00M | -$548.00M | -$562.00M |
| Free cash flow | $1.15B | $749.00M | $842.00M | $1.04B | $236.00M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | TEVA | $39.13 | -1.3% | 5.72M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Teva Pharmaceutical Industries Limited Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW